' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Tripolt, NJ; Aberer, F; Riedl, R; Url, J; Dimsity, G; Meinitzer, A; Stojakovic, T; Aziz, F; Hödl, R; Brachtl, G; Strunk, D; Brodmann, M; Hafner, F; Sourij, H;
Cardiovasc Diabetol. 2018; 17(1): 71
Originalarbeiten (Zeitschrift)


Brachtl Gabriele
Strunk Dirk


Early glucose lowering intervention in subjects with type 2 diabetes mellitus was demonstrated to be beneficial in terms of micro- and macrovascular risk reduction. However, most of currently ongoing cardiovascular outcome trials are performed in subjects with manifest atherosclerosis and long-standing diabetes. Therefore, the aim of this study is to investigate the effects of the dipeptidylpeptidase-4 inhibitor linagliptin in subjects with coronary artery disease (CAD) but early type 2 diabetes mellitus (T2DM) on a set of cardiovascular surrogate measurements.